Global

SHERIDAN, WYOMING - December 4, 2025 - TELEO Capital portfolio company Sharpen Technologies, Inc. ("SharpenCX") is expanding its reach in the communications platform market with the acquisition of Ytel, Inc., adding developer-centric CPaaS capabilities to its cloud-native customer engagement stack. The deal positions SharpenCX to serve enterprises that want to unify contact center, telephony and programmable messaging on a single, AI-ready platform rather than relying on multiple point solutions.

Strategic move in a consolidating CX and CPaaS landscape

SHERIDAN, WYOMING - December 4, 2025 - Thumzup Media Corporation is moving quickly to shed its image as a niche social advertising startup and reposition itself as a diversified operator in digital-asset infrastructure, data-center capacity, and next-generation computation. Backed by fresh capital and a pipeline of deals, the Los Angeles-based company is steering toward businesses with more predictable cash flows and scalable hard assets.

From Social Ad Startup to Balance-Sheet Builder

Thumzup's strategic reset rests on a markedly stronger financial base. In August 2025, the company raised $50 million in a public offering, lifting total assets to approximately $52 million. That step-change in scale gives Thumzup, which previously operated with far leaner resources, a genuine platform to pursue acquisitions, infrastructure buildouts, and selective minority stakes across high-growth technology verticals.

SHERIDAN, WYOMING - December 4, 2025 - Life sciences dealmaking is regaining momentum after a period of macroeconomic caution, but new research from West Monroe shows that transaction volume alone will not determine who comes out ahead. Instead, success in the next wave of M&A will hinge on execution speed, AI and digital maturity, and the ability to integrate people and cultures without losing focus on the deal thesis.

Dealmaking Rebounds, but the Rules Have Changed

West Monroe's report, The Next Wave of Life Sciences M&A: Navigating Policy, Power, and Progress, combines practitioner insight with a survey of 250 private equity firms and strategic acquirers in life sciences. The findings point to a clear rebound in activity: 68% of respondents expect more acquisitions in the next two years, while only 7% plan no deals at all.

SHERIDAN, WYOMING - December 4, 2025 - Info-Tech Research Group has released its 2025 Network Monitoring Data Quadrant Report, spotlighting six user-rated "champion" platforms that promise deeper visibility, faster incident response and stronger operational resilience for enterprise networks. Built entirely on verified end-user feedback from its SoftwareReviews platform, the new rankings give CIOs and network leaders a peer-validated lens on which tools are delivering real value in increasingly complex and threat-exposed environments.

Data-Driven Rankings for an Always-On Network Economy

SHERIDAN, WYOMING - December 4, 2025 - Blend360 has been named Sustainability Partner of the Year - LATAM and Public Sector Solution Provider Program Partner of the Year in the 2025 AWS Partner Awards, highlighting how AI- and cloud-driven analytics are moving to the center of sustainability and public sector modernization across Latin America and beyond. Announced at AWS re:Invent in Las Vegas, the dual recognition positions Blend360 as a key services partner for governments and institutions looking to use Amazon Web Services (AWS) for climate resilience and better resource allocation.

AWS Honors Partners Driving Innovation and Real-World Impact

SHERIDAN, WYOMING - December 4, 2025 - Workday has secured its position as a four-time Leader in the 2025 Gartner® Magic Quadrant™ for Financial Planning Software, underscoring how the company's AI-enabled platform is becoming a strategic hub for finance teams navigating volatility, pricing pressure and tighter capital markets. The recognition highlights Workday Adaptive Planning's role in helping financial planning and analysis (FP&A) organizations shift from static budgeting to always-on, scenario-based planning.

Four Years as a Gartner Leader in Financial Planning

SHERIDAN, WYOMING - December 4, 2025 - Ubicquia has unveiled a coordinated next-generation smart streetlighting portfolio built around its new UbiCell® Micro controller, major enhancements to the UbiVu® infrastructure management platform and the launch of UbiScout™, an AI video accessory that turns existing streetlights into multi-purpose urban sensors for safety, mobility and energy efficiency.

Integrated portfolio targets utilities and cities under pressure to modernize

With grid operators and municipalities facing rising energy costs, decarbonization targets and aging infrastructure, Ubicquia's new offering is designed to make large-scale modernization of streetlighting networks faster and more manageable. The company positions the portfolio as a way to deliver asset intelligence, remote control and AI analytics without wholesale replacement of installed luminaires.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics is expanding its Cell Line Development Center of Excellence through a new partnership with ATUM, integrating the Leap-In Transposase® expression platform to help biopharma developers move monoclonal antibodies and complex next-generation biologics into the clinic faster and more cost-effectively.

New options for faster, more flexible cell line development

As pressure grows to launch high-value biologics at lower cost, drug sponsors are looking for cell line development (CLD) solutions that combine speed, robustness and scalability. AGC Biologics' collaboration with ATUM adds a modern transposase-based expression platform to its CLD toolkit, creating a menu of fit-for-purpose options for standard monoclonals, multi-specific antibodies and other complex molecules.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics has signed a strategic development and manufacturing agreement with Repair Biotechnologies to advance a novel mRNA therapeutic aimed at rapidly stabilizing and shrinking atherosclerotic plaques, addressing what both partners describe as the leading single cause of human mortality worldwide.

Targeting plaque biology in a high-burden cardiovascular market

The collaboration focuses on an mRNA-based therapy designed to stabilize and reduce atherosclerotic plaques in major blood vessels, directly tackling the root pathology behind heart attacks and strokes. Rupture of unstable plaque and subsequent thrombotic events account for an estimated 27% of all human deaths, underscoring the strategic importance of any technology capable of reversing or halting plaque progression.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics is partnering with public benefit company Rarity PBC to bring a potentially life-saving gene therapy for Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) through commercial manufacturing and toward FDA approval, underscoring how CDMO collaborations are becoming central to translating academic breakthroughs into scalable rare disease treatments.

From transformational trials to a U.S. commercial pathway

Under the new agreement, AGC Biologics will provide end-to-end development and GMP manufacturing for Rarity's ex vivo autologous gene therapy RDP-101. If approved, RDP-101 would become the first gene therapy commercially available in the United States to reverse ADA-SCID, a rare inherited immunodeficiency that leaves infants dangerously exposed to severe, recurrent infections.